Myomo at H.C. Wainwright conference: referral shift drives growth

On Wednesday, September 16, 2026, Myomo CEO Paul R. Gudonis and CFO David Henry presented the company's growth story at the H.C. Wainwright 28th Annual Global Investment Conference. Myomo, which develops robotic prosthetics for individuals with chronic arm paralysis, reported a significant shift in its business model, driven by Medicare coverage and referral-based growth.

The company's sales model has evolved from direct-to-consumer marketing to partnerships with hospitals, therapists, and orthotic and prosthetic clinics, referred to as MyoConnect. This change has resulted in a 940 basis point increase in gross margin to 72%, driven by pricing adjustments, cost cuts, and higher volume. Myomo expects 2026 revenue of $45 million to $47 million, with annual cash burn down to about $7 million, a 61% improvement from 2025.

The company now serves approximately 4,000 patients and sells 80 to 100 units monthly. With a strong financial profile, Myomo has about $45 million in revenue, trades on the NYSE American, and is on track to reach free cash flow breakeven at about $15 million in quarterly revenue. The company maintains a current ratio of 2.31, ensuring liquid assets comfortably exceed short-term obligations.

Myomo's growth is supported by several key drivers, including MyoPro 3.0 for Germany, a pediatric product, and a clinical trial to broaden coverage. The company's referral ecosystem, which has a conversion rate 10 times higher than direct-to-consumer advertising, plays a critical role in its growth strategy.